Medical/Pharmaceuticals
SECuRE trial to continue with no modifications to protocol following Safety Review Committee meeting
HIGHLIGHTS * Following an interim data review of the Cohort Expansion Phase (Phase II) of the SECuRE trial, the Safety Review Committee (SRC) confirms the trial will continue with no modifications to the protocol. Patient population * With the SECuRE trial continuing to recruit, a total of n...
2026-01-15 22:02
1039
Recognition beyond borders: the life-long commitment of "Grandpa Sugar Pill"
BEIJING, Jan. 15, 2026 /PRNewswire/ -- A news report from China.org.cn on Gu Fangzhou, the father of sugar pills — a live oral polio vaccine:   Recognition beyond borders: the life-long commitment of "Grandpa Sugar Pill" Small, sweet, and slightly gritty when dissolved on the...
2026-01-15 22:00
967
Aphranel Convenes Cadaver Dissection Class in Thailand Successfully
BANGKOK, Jan. 14, 2026 /PRNewswire/ -- The inaugural "Moyom Biotech • Aphranel Global Expert Advisory Panel • Thailand Anatomy Exchange Conference" was successfully convened inThailand. This high-level forum gathered leading experts from multipleAsia-Pacific countries. Through this concentrated ...
2026-01-15 17:51
1577
GCCL and OPIS Announce Strategic Collaboration to Advance Global Clinical Trial Capabilities
YONGIN, South Korea, Jan. 15, 2026 /PRNewswire/ -- GCCL, a leading South Korea -based provider of clinical trial sample analysis, and OPIS, a global full-service contract research organization (CRO), have signed a Memorandum of Understanding (MOU) on the sidelines of the 44th Annual J.P. Morgan He...
2026-01-15 15:31
1106
JPM Highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO Platform Delivering Sustainable High Growth
* Total of 945 integrated projects in 2025, including 74 Phase III clinical projects and 25 commercial manufacturing projects * 209 new integrated projects in 2025 set a new record, with approximately 50% originating from U.S. clients * Complex modalities are WuXi Biologics' core growth engi...
2026-01-15 12:00
1539
Hyundai Bioscience Confirms Entry into U.S. FDA Phase 2 Trials for Broad-Spectrum Antiviral 'XAFTY' Following 2026 Biotech Showcase Consensus
- UCSD's Dr. Davey Smith, former ACTIV-2 Protocol Chair, endorses 'Xafty' as "The weapon to end the virus war." - Announces "One Drug, Two Tracks" strategy: Targeting Dengue in Vietnam and Respiratory Viruses (Flu, COVID, RSV) in the U.S. with the same drug. - Dr. Davey Smith: "With this multi-v...
2026-01-15 11:34
1370
Yuyu Pharma Establishes UCLA Office to Accelerate U.S. Pet Industry Expansion
SEOUL, South Korea, Jan. 14, 2026 /PRNewswire/ -- Yuyu Bio and Mervyn's Petcare, pet-focused subsidiaries of Yuyu Pharma, have opened a new office on theUCLA campus, strengthening the company's presence in the United States pet and animal health market. The two companies are now based at Magni...
2026-01-14 22:00
1959
Head-to-Head Real-World Data: Cadonilimab Outperforms PD-1 Inhibitors in First-Line PD-L1-Low Gastric Cancer
HONG KONG, Jan. 13, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced the presentation of a real-world study at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI), comparing cadonilimab plus chemotherapy against a PD-1 inhibitor plus chemotherapy for th...
2026-01-14 11:54
1278
Celltrion presents innovative drug pipeline and U.S. manufacturing and R&D expansion strategy at the 44th Annual J.P. Morgan Healthcare Conference
* Celltrion outlines a blueprint for innovative drug development built on its antibody expertise * The company highlights its business strategy to scale U.S. manufacturing and R&D capabilities, strengthening its global supply chain, production and operations INCHEON, South Korea, Jan. 13, 202...
2026-01-14 09:18
1293
Ractigen Therapeutics Announces First Patient Dosed in Phase II Clinical Trial of RAG-17 for SOD1-ALS
NANTONG, China, Jan. 13, 2026 /PRNewswire/ -- Ractigen Therapeutics is pleased to announce that the first patient has been dosed in the Phase II clinical trial of RAG-17, an innovative siRNA therapy targeting SOD1-mutated amyotrophic lateral sclerosis (ALS). The initial dosing occurred at Second ...
2026-01-13 20:30
784
Immunofoco Presents Phase I/IIa Data of IMC002 at ASCO GI 2026, Highlighting a Durable Complete Response Beyond One Year and a 66.7% ORR in Advanced GC/GEJ
SHANGHAI, Jan. 13, 2026 /PRNewswire/ -- Immunofoco, a clinical-stage biotechnology company advancing innovative CAR-T cell therapies for solid tumors, recently announced clinical data from its Phase I/IIa study of IMC002, a VHH-based anti-CLDN18.2 CAR-T therapy, in patients with advanced gastric ...
2026-01-13 16:26
1152
WuXi Biologics Obtains GMP Certification from UK MHRA for Commercial Manufacturing of an Ophthalmic Biologic
WUXI, China, Jan. 12, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that two of its manufacturing facilities in Wuxi –Drug Product Facility 5 (DP5) and Drug Product Packaging Center (DPPC) – have r...
2026-01-13 11:07
455
WuXi Biologics Obtains GMP Certification from UK MHRA for Commercial Manufacturing of an Ophthalmic Biologic
WUXI, China, Jan. 12, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that two of its manufacturing facilities in Wuxi –Drug Product Facility 5 (DP5) and Drug Product Packaging Center (DPPC) – have r...
2026-01-13 11:07
349
Abbisko Therapeutics Announces FDA Acceptance of the NDA for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor
SHANGHAI, Jan. 12, 2026 /PRNewswire/ -- 13 January 2026 (Beijing Time), Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) announcedtoday that the New Drug Application (NDA) for its novel, orally administered, highly selective, and potent small-molecule colony-...
2026-01-13 08:54
324
Abbisko Therapeutics Announces FDA Acceptance of the NDA for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor
SHANGHAI, Jan. 12, 2026 /PRNewswire/ -- 13 January 2026 (Beijing Time), Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) announcedtoday that the New Drug Application (NDA) for its novel, orally administered, highly selective, and potent small-molecule colony-...
2026-01-13 08:54
353
AbbVie and Trump Administration Reach Agreement to Improve Access and Affordability for Americans
* AbbVie will provide low prices in Medicaid, and expand affordable, direct-to-patient offerings for treatments used by millions of Americans through TrumpRx * AbbVie will commit $100 billion in U.S. research and development (R&D) and capital investments, including manufacturing, over the nex...
2026-01-13 07:30
176
Datasea Announces Major Acoustic Technology Advancements in Brain-Computer Interface Applications
Acoustic-Driven Technologies Poised to Support Embodied Intelligence and Health Robotics Applications in a Multi-Billion-Dollar Brain–Computer Interface Market BEIJING, Jan. 12, 2026 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), a technology company specializing in aco...
2026-01-12 22:30
290
Deepson Bio Receives Presidential Award at 2025 Korea Invention Patent Exhibition
Award highlights promise of ultrasound-based innovation in addressing unmet needs in dementia treatment SEOUL, South Korea, Jan. 12, 2026 /PRNewswire/ -- Deepson Bio Co., Ltd., a medical technology company focused on ultrasound-based approaches to dementia treatment, was honored with the Preside...
2026-01-12 22:00
341
LumiMind Wins SPEED AWARD at CES 2026 for Innovative Non-Invasive Sleep Technology With Real-Time EEG
LAS VEGAS, Jan. 12, 2026 /PRNewswire/ -- LumiMind, a next-generation
neurotechnology company advancing non-invasive brain health solutions, today
announced that it has won theSPEED AWARD at CES 2026 for its breakthrough
consumer sleep technology,LumiSleep.
2026-01-12 22:00
301
Insilico Medicine Completes First Patient First Dose in BETHESDA: A Phase II Trial for Garutadustat (ISM5411), the Gut-restricted AI-driven PHD Inhibitor for the Treatment of Inflammatory Bowel Disease
CAMBRIDGE, Mass., Jan. 12, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico"),
a clinical-stage, generative AI-driven drug discovery company, today announced
the completion of first patient first dose in BETHESDA: a Phase IIa clinical
trial of ISM5411 (NCT07265570
2026-01-12 21:30
276
Week's Top Stories
Most Reposted
Visa Supports Chinese Cardholders to Add Cards to Apple Pay for a More Convenient and Secure Payment Experience
[Picked up by 309 media titles]
2026-01-15 13:00Colebrook Bosson Saunders Launches Lana: An Adaptable Laptop Stand Engineered for Hybrid Work
[Picked up by 305 media titles]
2026-01-12 16:16
Ready Server Announces Strategic Expansion into Japan with AT TOKYO Data Centre
[Picked up by 301 media titles]
2026-01-13 13:16
CAYIN AI: Revolutionizing Creativity and Global Communication
[Picked up by 300 media titles]
2026-01-12 16:34
JIOS Aerogel® Secures Hyundai Contract Through New Licensing Model
[Picked up by 299 media titles]
2026-01-15 10:00Most Read
Daira Partners with Infinix, itel and Tecno to Expand Affordable Smartphone Access in Pakistan
2026-01-09 13:55
6814
Ribo Life Science (06938.HK) Successfully Lists on the Main Board of the Hong Kong Stock Exchange
2026-01-09 13:07
6238
TCL Earns Multiple CES 2026 Awards for Breakthrough Innovations Across TV, Mobile, and Smart Home Categories
2026-01-10 01:00
5331
Invitation to media and analyst briefing for Ericsson Q4 2025 report
2026-01-09 15:28
5204